Nivolumab for advanced squamous cell lung cancer: what are the next steps?

doi:10.1016/S1470-2045(15)70074-4

Comment

. 2015 Mar;16(3):234-5.

doi: 10.1016/S1470-2045(15)70074-4. Epub 2015 Feb 20.

Nivolumab for advanced squamous cell lung cancer: what are the next steps?

Ramon Andrade de Mello¹, Inés Pousa², Deolinda Pereira²

Affiliations

¹ Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal; Department of Medical Oncology, Portuguese Oncology Institute, Porto, Portugal. Electronic address: ramello@ualg.pt.
² Department of Medical Oncology, Portuguese Oncology Institute, Porto, Portugal.

PMID: 25704436
DOI: 10.1016/S1470-2045(15)70074-4

Comment

Nivolumab for advanced squamous cell lung cancer: what are the next steps?

Ramon Andrade de Mello et al. Lancet Oncol. 2015 Mar.

. 2015 Mar;16(3):234-5.

doi: 10.1016/S1470-2045(15)70074-4. Epub 2015 Feb 20.

Authors

Ramon Andrade de Mello¹, Inés Pousa², Deolinda Pereira²

Affiliations

¹ Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal; Department of Medical Oncology, Portuguese Oncology Institute, Porto, Portugal. Electronic address: ramello@ualg.pt.
² Department of Medical Oncology, Portuguese Oncology Institute, Porto, Portugal.

PMID: 25704436
DOI: 10.1016/S1470-2045(15)70074-4

No abstract available

PubMed Disclaimer

Comment on

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Rizvi NA, et al. Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20. Lancet Oncol. 2015. PMID: 25704439 Free PMC article. Clinical Trial.

Cited by

Immunotherapy for lung cancer: for whom the bell tolls?
Madureira P, de Mello RA, de Vasconcelos A, Zhang Y. Madureira P, et al. Tumour Biol. 2015 Mar;36(3):1411-22. doi: 10.1007/s13277-015-3285-6. Epub 2015 Mar 4. Tumour Biol. 2015. PMID: 25736929 Review.
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.
Guo L, Zhang H, Chen B. Guo L, et al. J Cancer. 2017 Feb 10;8(3):410-416. doi: 10.7150/jca.17144. eCollection 2017. J Cancer. 2017. PMID: 28261342 Free PMC article. Review.
Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review.
Zhang Z, Chen Y, Ma M, Hao J, Ding R, Han L, Zou J, Zhang L, Meng Q, Qu X, Liu Y, Zhao M. Zhang Z, et al. Oncotarget. 2017 Jul 7;8(56):96453-96459. doi: 10.18632/oncotarget.19089. eCollection 2017 Nov 10. Oncotarget. 2017. PMID: 29221220 Free PMC article.
Potential role of immunotherapy in advanced non-small-cell lung cancer.
de Mello RA, Veloso AF, Esrom Catarina P, Nadine S, Antoniou G. de Mello RA, et al. Onco Targets Ther. 2016 Dec 16;10:21-30. doi: 10.2147/OTT.S90459. eCollection 2017. Onco Targets Ther. 2016. PMID: 28031719 Free PMC article. Review.
TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?
de Mello RA. de Mello RA. Ann Transl Med. 2016 May;4(9):185. doi: 10.21037/atm.2016.04.16. Ann Transl Med. 2016. PMID: 27275498 Free PMC article. No abstract available.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Nivolumab for advanced squamous cell lung cancer: what are the next steps?

Affiliations

Nivolumab for advanced squamous cell lung cancer: what are the next steps?

Authors

Affiliations

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical